The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
Search
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Excellence in innovation | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's commitment to innovation in pharmaceutical production, delivering cutting-edge solutions for your biopharmaceutical needs.
Boehringer Ingelheim acquires Global Stem cell Technology
Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health
Knowing the enemy: PRRS and PCVD
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
Pyramid® / Presponse®
The pyramid®/presponse® family of vaccines provides broad coverage for BVD types 1 and 2, IBR, BRSV, PI3 and Mannheimia haemolytica with only a single dose.
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
Quality
At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
cat feline diabetes medication treatment eu approval
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Careers: Winning with people
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
Transforming pig farming through AI
With our livestock farming technology based on sound analytics, we are improving pig farm practices, producing healthier pigs and a better farm economy.
The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Congress Patient Benefit
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
The little things
In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.
“Rare diseases are quite common”
Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
COVID-19 Protecting Our Employees
Boehringer Ingelheim has taken precautions to protect the health of employees and mitigate the risk of COVID-19 affecting our organization.
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments